India’s biotechnology industry has the potential to become a major driver of the country’s economy, but is challenged by one […]

I’ve been asked quite a bit recently to talk about my career path. I usually begin my talks by explaining

I previously posted how price controls and compulsory licensing give buyers more power … for a price and Abbott’s spat

In response to Thailand’s decision to issue compulsory licenses for Kaletra and for Plavix, effectively bypassing their patents by purchasing

Welcome to the April 10, 2007 edition of Carnival of Biotechnology. Finance and business development On Pharma presents a report

Following up on the success of “Building Biotechnology” (www.BuildingBiotechnology.com), I’m in the late stages of assembling a more advanced follow-up

Genentech is investing $140mm in a new biologic manufacturing plant in Singapore. The first commercial-scale microbial fermentation plant in Singapore,

I touched briefly on the Medimmune v. Genentech case in a previous Carnival of Biotechnology, but I didn’t go into